Methotrexate inhibits BMP4 and abrogates the hypertrophic chondrocyte phenotype of synovial fibroblasts in juvenile idiopathic arthritis

Abstract Background Juvenile Idiopathic Arthritis (JIA) induces growth disturbances in affected joints. Fibroblast-like synoviocytes (FLS) play a crucial role in JIA pathogenesis. FLS overexpress bone morphogenetic protein 4 (BMP4) and have a chondrocyte-like phenotype. FLS contribute directly to jo...

Full description

Bibliographic Details
Main Authors: Megan M. Simonds, Samuel T. Freer, Anne Marie C. Brescia
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Online Access:https://doi.org/10.1186/s12969-023-00940-6
_version_ 1827388653794492416
author Megan M. Simonds
Samuel T. Freer
Anne Marie C. Brescia
author_facet Megan M. Simonds
Samuel T. Freer
Anne Marie C. Brescia
author_sort Megan M. Simonds
collection DOAJ
description Abstract Background Juvenile Idiopathic Arthritis (JIA) induces growth disturbances in affected joints. Fibroblast-like synoviocytes (FLS) play a crucial role in JIA pathogenesis. FLS overexpress bone morphogenetic protein 4 (BMP4) and have a chondrocyte-like phenotype. FLS contribute directly to joint growth disturbances through endochondral bone formation. We investigated the ability of methotrexate to inhibit BMP4 expression and alter the hypertrophic chondrocyte-like phenotype of JIA FLS. Methods We selected primary cells from three subjects with persistent oligoarticular JIA, three subjects who eventually extended to a polyarticular disease course, which we termed extended-to-be (ETB), and three subjects who had polyarticular arthritis at time of diagnosis. We treated cells with methotrexate and two BMP4 inhibitors: noggin and chordin. We measured protein concentration from three chondrocyte cell markers: collagen II, aggrecan, and collagen X as well as BMP4. Results ColX, marker of chondrocyte hypertrophy, was significantly increased in polyarticular FLS when compared to both persistent FLS and ETB FLS, making polyarticular FLS the most like hypertrophic chondrocytes. Methotrexate caused significant decreases in BMP4 and ColX expression in persistent, ETB, and polyarticular FLS when compared to respective untreated cells. Ligand-binding BMP4 antagonists, noggin and chordin, caused significant decreases in ColX expression in FLS from all three disease courses and significant increases in collagen II protein, an early chondrocyte marker, when compared to respective untreated cells. Conclusions Methotrexate, the first-line therapy in the treatment of JIA, mimics BMP4 antagonists by effectively lowering BMP4 and ColX expression in FLS. Inhibiting FLS from undergoing hypertrophy could prevent these cells from contributing to joint growth disturbances via endochondral bone formation.
first_indexed 2024-03-08T16:22:00Z
format Article
id doaj.art-0c970fe87ca345f09b4b6dd2441dfedf
institution Directory Open Access Journal
issn 1546-0096
language English
last_indexed 2024-03-08T16:22:00Z
publishDate 2024-01-01
publisher BMC
record_format Article
series Pediatric Rheumatology Online Journal
spelling doaj.art-0c970fe87ca345f09b4b6dd2441dfedf2024-01-07T12:15:37ZengBMCPediatric Rheumatology Online Journal1546-00962024-01-012211810.1186/s12969-023-00940-6Methotrexate inhibits BMP4 and abrogates the hypertrophic chondrocyte phenotype of synovial fibroblasts in juvenile idiopathic arthritisMegan M. Simonds0Samuel T. Freer1Anne Marie C. Brescia2Nemours Biomedical ResearchNemours Biomedical ResearchNemours Children’s Health, DelawareAbstract Background Juvenile Idiopathic Arthritis (JIA) induces growth disturbances in affected joints. Fibroblast-like synoviocytes (FLS) play a crucial role in JIA pathogenesis. FLS overexpress bone morphogenetic protein 4 (BMP4) and have a chondrocyte-like phenotype. FLS contribute directly to joint growth disturbances through endochondral bone formation. We investigated the ability of methotrexate to inhibit BMP4 expression and alter the hypertrophic chondrocyte-like phenotype of JIA FLS. Methods We selected primary cells from three subjects with persistent oligoarticular JIA, three subjects who eventually extended to a polyarticular disease course, which we termed extended-to-be (ETB), and three subjects who had polyarticular arthritis at time of diagnosis. We treated cells with methotrexate and two BMP4 inhibitors: noggin and chordin. We measured protein concentration from three chondrocyte cell markers: collagen II, aggrecan, and collagen X as well as BMP4. Results ColX, marker of chondrocyte hypertrophy, was significantly increased in polyarticular FLS when compared to both persistent FLS and ETB FLS, making polyarticular FLS the most like hypertrophic chondrocytes. Methotrexate caused significant decreases in BMP4 and ColX expression in persistent, ETB, and polyarticular FLS when compared to respective untreated cells. Ligand-binding BMP4 antagonists, noggin and chordin, caused significant decreases in ColX expression in FLS from all three disease courses and significant increases in collagen II protein, an early chondrocyte marker, when compared to respective untreated cells. Conclusions Methotrexate, the first-line therapy in the treatment of JIA, mimics BMP4 antagonists by effectively lowering BMP4 and ColX expression in FLS. Inhibiting FLS from undergoing hypertrophy could prevent these cells from contributing to joint growth disturbances via endochondral bone formation.https://doi.org/10.1186/s12969-023-00940-6Juvenile idiopathic arthritisMethotrexateBone morphogenetic protein 4SynoviocytesChondrocytes
spellingShingle Megan M. Simonds
Samuel T. Freer
Anne Marie C. Brescia
Methotrexate inhibits BMP4 and abrogates the hypertrophic chondrocyte phenotype of synovial fibroblasts in juvenile idiopathic arthritis
Pediatric Rheumatology Online Journal
Juvenile idiopathic arthritis
Methotrexate
Bone morphogenetic protein 4
Synoviocytes
Chondrocytes
title Methotrexate inhibits BMP4 and abrogates the hypertrophic chondrocyte phenotype of synovial fibroblasts in juvenile idiopathic arthritis
title_full Methotrexate inhibits BMP4 and abrogates the hypertrophic chondrocyte phenotype of synovial fibroblasts in juvenile idiopathic arthritis
title_fullStr Methotrexate inhibits BMP4 and abrogates the hypertrophic chondrocyte phenotype of synovial fibroblasts in juvenile idiopathic arthritis
title_full_unstemmed Methotrexate inhibits BMP4 and abrogates the hypertrophic chondrocyte phenotype of synovial fibroblasts in juvenile idiopathic arthritis
title_short Methotrexate inhibits BMP4 and abrogates the hypertrophic chondrocyte phenotype of synovial fibroblasts in juvenile idiopathic arthritis
title_sort methotrexate inhibits bmp4 and abrogates the hypertrophic chondrocyte phenotype of synovial fibroblasts in juvenile idiopathic arthritis
topic Juvenile idiopathic arthritis
Methotrexate
Bone morphogenetic protein 4
Synoviocytes
Chondrocytes
url https://doi.org/10.1186/s12969-023-00940-6
work_keys_str_mv AT meganmsimonds methotrexateinhibitsbmp4andabrogatesthehypertrophicchondrocytephenotypeofsynovialfibroblastsinjuvenileidiopathicarthritis
AT samueltfreer methotrexateinhibitsbmp4andabrogatesthehypertrophicchondrocytephenotypeofsynovialfibroblastsinjuvenileidiopathicarthritis
AT annemariecbrescia methotrexateinhibitsbmp4andabrogatesthehypertrophicchondrocytephenotypeofsynovialfibroblastsinjuvenileidiopathicarthritis